{"denoms":[{"counts":[{"groupId":"BG000","value":"337"},{"groupId":"BG001","value":"170"},{"groupId":"BG002","value":"507"}],"units":"Participants"}],"groups":[{"description":"Participants received 35 mg/m\\^2 of TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"BG000","title":"TAS-102+BSC"},{"description":"Participants received 35 mg/m\\^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.","id":"BG001","title":"Placebo+BSC"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.78","value":"62.8"},{"groupId":"BG001","spread":"10.04","value":"62.0"},{"groupId":"BG002","spread":"10.53","value":"62.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"138"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"252"},{"groupId":"BG001","value":"117"},{"groupId":"BG002","value":"369"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"244"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"357"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}],"title":"Black/African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"29"},{"groupId":"BG002","value":"80"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"62"}]}],"title":"Not collectable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"191"}]}],"title":"ECOG Grade 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"214"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"316"}]}],"title":"ECOG Grade 1"}],"description":"The ECOG performance status was used to evaluate participant's disease progression and the effect of the disease on the participant's activities of daily living. It ranged on the scale from 0-5 (0 equal to \\[=\\] normal activity; 1= symptoms but ambulatory; 2= in bed for less than (\\<) 50 percent (%) of the time; 3= in bed for greater than (\\>) 50% of the time; 4= 100% bedridden; 5= dead). Time to definitive deterioration in ECOG performance status score from baseline was defined as change from 0, 1 to greater than or equal to (\\>=2), or from 2 to \\>=3.","paramType":"COUNT_OF_PARTICIPANTS","title":"European Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"Analysis was performed on the Intent-to-Treat (ITT) population that included all randomized participants, regardless of whether or not study treatment was administered."}